News Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
397.4 ^USD	+0.20%		-1.70%	-2.34%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Apr. 11	Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Wall Street rebounds on softer inflation data, eyes on earnings	Apr. 11	RE
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11
Nasdaq set for higher open as fresh inflation data allays rate jitters	Apr. 11	RE
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell	Apr. 11	MT
Sector Update: Health Care	Apr. 11	MT
HC Wainwright Raises Vertex Pharmaceuticals' Price Target to $462 From $457, Maintains Buy Rating	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT
Top Premarket Gainers	Apr. 11	MT
Vertex Pharmaceuticals' $4.9 Billion Deal for Alpine Shows Lead-Candidate's Potential, Analysts Say	Apr. 11	MT
Evercore ISI Upgrades Vertex Pharmaceuticals to Outperform From In Line	Apr. 11	MT
News Highlights : Top Company News of the Day - Thursday at 7 AM ET	Apr. 11	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal	Apr. 11	MT
Futures slip as rate-cut hopes ebb	Apr. 11	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST